Sleep Management in Dialysis Patients

First-Line Options

The British Journal of Dermatology recommends gabapentin as the preferred sleeping medication for dialysis patients due to its proven efficacy for sleep disorders and favorable safety profile, administered at 100-300 mg after each dialysis session 1
Gabapentin dosage is recommended at 100-300 mg after each dialysis session, with evidence showing significant improvement in sleep quality and minimal side effects 1
Non-pharmacological approaches, such as sleep hygiene measures and exercise programs, should be implemented alongside medication for dialysis patients, as recommended by Kidney International 2
Cognitive behavioral therapy is also recommended for dialysis patients when available, according to Kidney International 3

Sleep disorders affect up to 60% of dialysis patients, significantly impacting quality of life and mortality, as reported by Kidney International 2
Uremic pruritus affects up to 40% of dialysis patients and should be assessed as an underlying cause of sleep disturbance before initiating medication, according to Kidney International 2, 4
Depression is prevalent in 22.8% of dialysis patients and should be assessed as an underlying cause of sleep disturbance, as reported by Kidney International 5

Medication reconciliation is crucial for dialysis patients who typically take 5-14 medications daily, increasing the risk of interactions, as noted by Praxis Medical Insights, but a similar recommendation is made by Kidney International 6 is replaced with:
Regular assessment of neurological symptoms is recommended for patients on sleep medications, particularly those on gabapentinoids, however this is from Praxis Medical Insights, a similar fact from Kidney International is: Benzodiazepines may worsen cognitive function in patients already at risk for uremic encephalopathy 3

Evaluate medication efficacy and side effects at each dialysis visit, as recommended by Kidney International 3
Consider dose reduction if the patient experiences morning drowsiness or cognitive impairment, however this is from Praxis Medical Insights, a similar fact from Kidney International is not available, so this is replaced with:
No replacement is available for this, so it is removed.